Seeking Alpha

John H. Ford's  Instablog

John H. Ford
Send Message
For the past 30 years, I have been involved in startups, as a founder, and active investor. My first company was purchased by Johnson & Johnson, which set the foundation for future investments. My level of trading escalated after graduating from college, primarily as a result of my... More
View John H. Ford's Instablogs on:
  • Top Trade Competition Begins Monday

    On Monday, December 1, I will be announcing the first in a series of John Ford Top Trade Competitions. If you are following a company that represents a great short-term trade, enter your analysis because if you win this competition, your company will be presented to a large Wall Street audience. Competition rules, deadlines, and entry categories will be explained in detail on December 1.

    Nov 28 9:30 AM | Link | Comment!
  • I Am Long Cynapsus Therapeutics

    I have initiated a long position in Cynapsus Therapeutics (OTCQX:CYNAF). The company will soon be reporting Phase 2 data, and if the data is positive, Cynapsus should be valued above $500 million, equal to that of its closest competitor Civatas which was recently purchased for $525 million cash. Cynapsus is currently valued at $56 million, has $18 million in cash, and no debt. I will publish a detailed analysis once the company completes its NASDAQ up listing.

    Disclosure: The author is long CYNAF.

    Nov 06 9:57 AM | Link | 17 Comments
  • One Of The Best Biotech Trades I Have Ever Encountered

    I will be releasing a new article this week, but only to my subscribers.

    Here's the sequence of events:

    1st event: I will release the entire article to my subscribers.

    2nd event: Within 24 hours I will publish a micro analysis along with the company ticker on Seeking Alpha and Twitter.

    3rd event: Once the company completes its NASDAQ uplisting, I will publish the entire article on Seeking Alpha.

    This company presents one of the most ideal biotech trades I've ever encountered. If it delivers positive Phase 2 data, which is highly likely given past data, the company should be valued at the same level of its primary competitor; over $500 million. The market is completely unaware of this company, which is why its current valuation is a ridiculously low $50 million.

    But what makes this trade even better, is that the FDA approved an accelerated clinical path, which makes this a relatively low risk trade. Additionally, NASDAQ up listing is imminent, the company has a strong balance sheet, and its technology has been endorsed by industry leaders and Big Pharma. This trade could provide a 2X to 5X short-term return. Longer-term, we could see a 10X return.

    If you would like to receive this article, please click here.

    Nov 03 12:34 PM | Link | 2 Comments
Full index of posts »
Latest Followers


More »

Latest Comments

Posts by Themes
Instablogs are Seeking Alpha's free blogging platform customized for finance, with instant set up and exposure to millions of readers interested in the financial markets. Publish your own instablog in minutes.